Clinical trials: Ductal Carcinoma
Breast Ductal Carcinoma In Situ, COVID-19 Infection
Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery
This study investigates the impact of COVID-19 pandemic on out-of-pocket costs, lost wages, and unemployment in patients with breast cancer undergoing breast surgery.
- Conditions
- Breast Ductal Carcinoma In Situ, COVID-19 Infection, Hereditary Breast Carcinoma, Invasive Breast Carcinoma
- Trial name
- NCT04169542
- Testing
- Questionnaire Administration
- Where
- 4 sites in United States
- Volunteers
- 600 people
- Sponsor
- M.D. Anderson Cancer Center
Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC)
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Background: Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in cancer-associated fibroblasts of certain cancer types.
- Conditions
- Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC), Mesothelioma, Pheochromocytoma/Paraganglioma (PPGL)
- Trial name
- NCT06503146
- Testing
- [18F]FAPI-74, [18F]FDG
- Where
- United States
- Volunteers
- 320 people
- Sponsor
- National Cancer Institute (NCI)
Salivary Gland Cancer, Salivary Duct Carcinoma
Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients
Phase 2 pilot study, which evaluates the safety and efficacy of Lutetium-177-PSMA radioligand therapy in advanced salivary gland cancer patients.
- Conditions
- Salivary Gland Cancer, Salivary Duct Carcinoma, Adenoid Cystic Carcinoma
- Trial name
- LUPSA (NCT04291300)
- Testing
- Lutetium-177-PSMA-I&T
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Radboud University Medical Center
Breast Cancer
Clinical Trial of Trametes Versicolor in Women With Breast Cancer
RATIONALE: Coriolus versicolor mushroom extract may slow the growth of cancer cells and may be an effective treatment for breast cancer.
- Trial name
- NCT00680667
- Testing
- Coriolus versicolor extract
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Ductal Carcinoma in Situ of the Breast
Avoiding Surgery in Estrogen Receptor Positive Atypical Ductal Hyperplasia and In-situ Carcinoma Treated With Endocrine Treatment Trial
This study aims to evaluate the 5-year invasive ipsilateral breast cancer incidence rate in patients with hormone-receptor positive, HER-2 negative atypical ductal hyperplasia or in-situ carcimona who omitted surgery and received…
- Trial name
- ASAIN (NCT07245316)
- Testing
- Avoiding surgery
- Where
- South Korea
- Volunteers
- 340 people
- Sponsor
- Jeong Eon Lee
Breast Cancer, Osteoporosis
Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS
RATIONALE: Bisphosphonates, such as risedronate, may help improve bone health and prevent osteoporosis in postmenopausal women. It is not yet known whether risedronate is effective in improving bone mineral density and bone…
- Trial name
- NCT00324714
- Testing
- risedronate sodium, diagnostic laboratory biomarker analysis
- Where
- 2 sites in Switzerland
- Sponsor
- ETOP IBCSG Partners Foundation
Medullary Thyroid Carcinoma
ImmunoTEP for Patients With Medullary Thyroid Carcinoma.
The aim of this study is to optimize pretargeting parameters using pharmacokinetic and imaging data for immuno-PET using anti-CEA x anti-HSG TF2 BsMAb and 150 MBq of 68Ga-IMP-288 peptide in MTC patients with abnormal Ct serum…
- Trial name
- iTEP-CMT (NCT01730638)
- Testing
- • TF2 and 68 Ga-IMP-288
- Where
- 3 sites in France
- Volunteers
- 25 people
- Sponsor
- Nantes University Hospital
Breast Cancer, Contralateral Breast Cancer
Magnetic Resonance Imaging in Women Recently Diagnosed With Unilateral Breast Cancer
RATIONALE: Diagnostic procedures such as magnetic resonance imaging (MRI) may improve the ability to detect cancer in the unaffected breast of women recently diagnosed with unilateral breast cancer.
- Trial name
- ACRIN-6667 (NCT00058058)
- Testing
- MRI
- Where
- 21 sites in United States, Canada and 1 more
- Volunteers
- 1,007 people
- Sponsor
- American College of Radiology Imaging Network
Breast Cancer
Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy may kill more tumor cells.
- Trial name
- NCT00002967
- Testing
- cyclophosphamide, doxorubicin hydrochloride, octreotide pamoate
- Where
- 108 sites in United States, Canada
- Sponsor
- NSABP Foundation Inc
Pancreatic Adenocarcinoma
HER-2 Expression in Pancreatic Duct Adenocarcinoma
Pancreatic duct adenocarcinoma is a highly aggressive carcinoma that is associated with a poor prognosis. Detection of novel biological markers that are specifically over expressed in pancreatic duct adenocarcinoma and their…
- Trial name
- NCT06055647
- Testing
- immunohistochemical approach
- Volunteers
- 37 people
- Sponsor
- Sohag University
Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma
Peritumoral MRE Stiffness for Predicting Resection Margin Status and Recurrence in Liver Cancer
Microscopic residual tumor at the resection margin is a critical risk factor for recurrence in patients undergoing hepatectomy for liver cancer, yet current detection relies solely on postoperative pathological examination of the…
- Conditions
- Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT07704216
- Testing
- Three-Dimensional Magnetic Resonance Elastography
- Volunteers
- 150 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Breast Cancer
Partial Breast Radiation Therapy in Treating Women Undergoing Breast-Conserving Therapy for Early Stage Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Trial name
- NCT00527293
- Testing
- adjuvant therapy, 3-dimensional conformal radiation therapy, brachytherapy
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount of estrogen the body makes.
- Trial name
- NCT01439711
- Testing
- letrozole, MRI, conventional surgery
- Where
- 32 sites in United States
- Volunteers
- 108 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Ductal Carcinoma In Situ
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
This randomized phase III trial studies radiation therapy to see how well it works with or without trastuzumab in treating women with ductal carcinoma in situ who have undergone lumpectomy.
- Trial name
- NCT00769379
- Testing
- Laboratory Biomarker Analysis, Trastuzumab, Whole Breast Irradiation
- Where
- 1,260 sites in United States, Canada and 2 more
- Volunteers
- 2,014 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer
RATIONALE: Aromatase inhibitor therapy is used in treating postmenopausal women who have hormone-dependent breast cancer. It is not yet known what effect aromatase inhibitor therapy has on blood vessel function.
- Trial name
- NCT00719966
- Testing
- anastrozole, exemestane, letrozole
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Mayo Clinic
Advanced Solid Tumours
A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)
This study is to evaluate the preliminary efficacy and safety of RXC004 monotherapy and in combination with pembrolizumab in advanced solid tumours that have progressed following SoC treatment.
- Trial name
- KEYNOTE-E86 (NCT04907851)
- Testing
- RXC004, Denosumab, pembrolizumab
- Where
- 13 sites in Australia, United Kingdom
- Volunteers
- 45 people
- Sponsor
- Redx Pharma Ltd
Breast Cancer
Comparison of Biomarkers Based on Fine-Needle Aspiration in Women at Increased or Normal Risk of Breast Cancer
RATIONALE: Examining biomarkers in fine-needle aspiration specimens from women at risk for breast cancer may improve the ability to detect breast cancer cells early and plan effective treatment.
- Trial name
- NCT00041353
- Testing
- cytology specimen collection procedure, comparison of screening methods, study of high risk factors
- Sponsor
- Fox Chase Cancer Center
Diarrhea, Medullary Thyroid Cancer
The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
Diarrhea in patients with MTC (Medullary Thyroid Cancer) can be debilitating and, in some cases life threatening. Findings in such patients include volume depletion, renal insufficiency, and electrolyte disorders.
- Trial name
- NCT01739634
- Testing
- CASAD
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Salient Pharmaceuticals Incorporated
Paget Disease, Extramammary, Rhabdomyosarcoma
Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors
The goal of this clinical trial is to learn if albumin-paclitaxel, ifosfamide and cisplatin (Nab-TIP) works to treat advanced rare tumors including PAGET's disease of scrotum with infiltrating sweat gland carcinoma （cohort 1）…
- Conditions
- Paget Disease, Extramammary, Rhabdomyosarcoma, Testicular Cancer, Penile Cancer
- Trial name
- NCT06684327
- Testing
- Albumin-paclitaxel Injection
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
This phase II trial is studying how well MD2206 works in treating patients with advanced refractory biliary cancer that cannot be removed by surgery.
- Conditions
- Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma, Recurrent Gallbladder Carcinoma
- Trial name
- NCT01425879
- Testing
- Akt Inhibitor MK2206, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 8 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)